$NVCT
Nuvectis Pharma, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024002497 Filed on March 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.736M $2.601M $7.517M
YoY Change 0.12% 9.24% 25.14%
% of Gross Profit
Research & Development $2.660M $4.858M $15.38M
YoY Change 12.38% 10.48% 16.28%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.660M $6.866M $15.38M
YoY Change 12.38% 1.3% 16.28%
Operating Profit -$4.396M -$22.90M
YoY Change 7.19% 19.04%
Interest Expense $225.0K $244.0K $637.0K
YoY Change 332.69% 197.56% 327.52%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.171M -$6.622M -$22.26M
YoY Change 3.01% -1.11% 16.64%
Income Tax
% Of Pretax Income
Net Earnings -$4.171M -$6.622M -$22.26M
YoY Change 3.01% -1.11% 16.64%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25 -$1.43
Diluted Earnings Per Share -$0.25 -$0.41 -$1.43
COMMON SHARES
Basic Shares Outstanding 17.77M 17.33M 15.56M
Diluted Shares Outstanding 16.56M 15.56M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.46M $19.13M $19.13M
YoY Change 25.83% -4.34% -4.34%
Cash & Equivalents $19.50M $19.10M $19.13M
Short-Term Investments
Other Short-Term Assets $250.0K $59.00K $59.00K
YoY Change -66.22% -85.68% -85.68%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.71M $19.19M $19.19M
YoY Change 21.63% -5.98% -5.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $19.71M $19.19M $19.19M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $19.71M $19.19M $19.19M
YoY Change 21.63% -5.98% -5.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.759M $2.771M $2.771M
YoY Change -16.08% -4.78% -4.78%
Accrued Expenses $486.0K $415.0K $4.213M
YoY Change 211.54% -6.74% 49.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.692M $6.984M $6.984M
YoY Change 44.69% 12.9% 12.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.692M $6.984M $6.984M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.692M $6.984M $6.984M
YoY Change 44.69% 12.9% 12.9%
SHAREHOLDERS EQUITY
Retained Earnings -$58.40M -$54.20M
YoY Change 62.22% 69.38%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.02M $12.20M $12.20M
YoY Change
Total Liabilities & Shareholders Equity $19.71M $19.19M $19.19M
YoY Change 21.63% -5.98% -5.98%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$4.171M -$6.622M -$22.26M
YoY Change 3.01% -1.11% 16.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.358M -$3.850M -$15.95M
YoY Change -8.77% 9.5% 17.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.289M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.696M 917.0K 15.09M
YoY Change 1763.49% -800.0% -45.75%
NET CHANGE
Cash From Operating Activities -4.358M -3.850M -15.95M
Cash From Investing Activities 0.000
Cash From Financing Activities 4.696M 917.0K 15.09M
Net Change In Cash 338.0K -2.933M -867.0K
YoY Change -107.47% -19.58% -106.08%
FREE CASH FLOW
Cash From Operating Activities -$4.358M -$3.850M -$15.95M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15556655
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12657651
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001875558
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17418886
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15190720
CY2022Q4 nvct Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q4 nvct Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 nvct Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q4 nvct Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 nvct Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2023Q4 nvct Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2022Q4 nvct Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2023Q4 nvct Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2022Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2023Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15556655
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12657651
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41264
CY2023 dei Entity Registrant Name
EntityRegistrantName
NUVECTIS PHARMA, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2405608
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1 Bridge Plaza
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 275
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Lee
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07024
CY2023 dei City Area Code
CityAreaCode
201
CY2023 dei Local Phone Number
LocalPhoneNumber
614-3150
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per
CY2023 dei Trading Symbol
TradingSymbol
NVCT
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Public Float
EntityPublicFloat
60000000.0
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17768824
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
1309
CY2023 dei Auditor Name
AuditorName
PricewaterhouseCoopers International Limited
CY2023 dei Auditor Location
AuditorLocation
Tel-Aviv, Israel
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19126000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19993000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
59000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
412000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19185000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20405000
CY2023Q4 us-gaap Assets
Assets
19185000
CY2022Q4 us-gaap Assets
Assets
20405000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2771000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2910000
CY2022Q4 nvct Accrued Offering Costs
AccruedOfferingCosts
450000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
415000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
445000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3798000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2381000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6984000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6186000
CY2023Q4 us-gaap Liabilities
Liabilities
6984000
CY2022Q4 us-gaap Liabilities
Liabilities
6186000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17418886
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15190720
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66446000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
46204000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54245000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31985000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12201000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14219000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19185000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20405000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15380000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13227000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7517000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6007000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-22897000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-19234000
CY2023 nvct Finance Income
FinanceIncome
637000
CY2022 nvct Finance Income
FinanceIncome
149000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22260000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-19085000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22260000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19085000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15556655
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15556655
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12657651
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12657651
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-11008000
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
15246000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13108000
CY2022 nvct Stock And Warrants Issued During Period Value Common Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
14251000
CY2022 nvct Prefunded Warrants Issued During Period Value
PrefundedWarrantsIssuedDuringPeriodValue
0
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
1707000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-19085000
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14219000
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023 nvct Offering Cost On Exercise Of Preferred Investment Options
OfferingCostOnExerciseOfPreferredInvestmentOptions
755000
CY2023 nvct Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1479000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5114000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2023 us-gaap Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium
AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium
4705000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22260000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12201000
CY2023 us-gaap Profit Loss
ProfitLoss
-22260000
CY2022 us-gaap Profit Loss
ProfitLoss
-19085000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
4705000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1707000
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-353000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
321000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-139000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1851000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-30000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
338000
CY2023 nvct Increase Decrease In Accrued Compensation And Benefits
IncreaseDecreaseInAccruedCompensationAndBenefits
1417000
CY2022 nvct Increase Decrease In Accrued Compensation And Benefits
IncreaseDecreaseInAccruedCompensationAndBenefits
1951000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15954000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13559000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5289000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
174000
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
16000000
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
15879000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11192000
CY2023 nvct Payments Of Issuance Costs For Warrant Exercise And Preferred Investment Option
PaymentsOfIssuanceCostsForWarrantExerciseAndPreferredInvestmentOption
371000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15087000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27810000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-867000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14251000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19993000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5742000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19126000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19993000
CY2022 nvct Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
450000
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1 – GENERAL:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">a.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Nuvectis Pharma Inc. (the “Company”) was incorporated under the laws of the State of Delaware on July 27, 2020 and commenced its principal operations in May 2021. The Company’s principal executive offices are located at Fort Lee in the state of New Jersey.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company is a biopharmaceutical company, which operates as one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. The Company’s precision medicine approach translates key scientific insights relating to the oncogenic drivers and pathway addiction of cancer into potential potent and highly selective anticancer drugs.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">b.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In May 2021, the Company entered into a worldwide, exclusive license agreement with the CRT Pioneer Fund (“CRT”) (see note 5a). In August 2021, the Company entered into a worldwide, exclusive license agreement with the University of Edinburgh, Scotland for the Company’s second drug candidate (see note 5a).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Initial Public Offering</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On February 8, 2022, the Company’s shares began trading on the NASDAQ under symbol “NVCT” (see note 6b)</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Liquidity</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses since its inception and had an accumulated deficit of $54.2 million as of December 31, 2023. The Company had cash and cash equivalents of $19.1 million as of December 31, 2023 and has not generated positive cash flows from operations. To date, the Company has been able to fund its operations primarily through the issuance and sale of common shares and redeemable convertible preferred shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">During the year ended December 31, 2023, the Company sold a total of 371,743 shares of common stock under the ATM for aggregate total gross proceeds of approximately $5.3 million at an average selling price of $14.23 per share, resulting in net proceeds of approximately $5.1 million after deducting commissions and other transaction costs. See note 11.e for at-the-market activity subsequent to December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Based on management’s cash flow projections, the Company believes that the Company’s currently available cash and cash equivalents as of December 31, 2023 is sufficient to fund the Company’s planned operations for a period greater than 12 months from the issuance of these financial statements. The Company will need to raise additional capital in order to complete the clinical trials aimed at developing the product candidates until obtaining its regulation and marketing approvals. There can be no assurances that the Company will be able to secure such additional financing if at all, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force the Company to delay, limit, or reduce our products’ development, clinical trials, commercialization efforts or other operations, or even close down or liquidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54200000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19100000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Use of Estimates in the Preparation of Financial Statements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses, valuation of share based compensation awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">f.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Concentrations of Credit Risk</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company is subject to credit risk from holding its cash and cash equivalents at one commercial bank. The Company limits its exposure to credit losses by investing in money market accounts which are included in cash and cash equivalents through a U.S. bank with high credit ratings. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p>
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
14000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
13000
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
17100000
CY2023 nvct Research And Development Labor And Related Expense
ResearchAndDevelopmentLaborAndRelatedExpense
6310000
CY2022 nvct Research And Development Labor And Related Expense
ResearchAndDevelopmentLaborAndRelatedExpense
4648000
CY2023 nvct Clinical Expense
ClinicalExpense
4296000
CY2022 nvct Clinical Expense
ClinicalExpense
3714000
CY2023 nvct License Fees
LicenseFees
1001000
CY2022 nvct License Fees
LicenseFees
2297000
CY2023 us-gaap Manufacturing Costs
ManufacturingCosts
3495000
CY2022 us-gaap Manufacturing Costs
ManufacturingCosts
2170000
CY2023 nvct Research And Development Professional Fee
ResearchAndDevelopmentProfessionalFee
278000
CY2022 nvct Research And Development Professional Fee
ResearchAndDevelopmentProfessionalFee
398000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15380000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13227000
CY2023 us-gaap Professional Fees
ProfessionalFees
3460000
CY2022 us-gaap Professional Fees
ProfessionalFees
2381000
CY2023 us-gaap Labor And Related Expense
LaborAndRelatedExpense
2298000
CY2022 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1756000
CY2023 us-gaap General Insurance Expense
GeneralInsuranceExpense
842000
CY2022 us-gaap General Insurance Expense
GeneralInsuranceExpense
1183000
CY2023 nvct Travel Expenses
TravelExpenses
369000
CY2022 nvct Travel Expenses
TravelExpenses
262000
CY2023 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
548000
CY2022 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
425000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7517000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6007000
CY2023Q4 nvct Collaborative Agreement Amount Utilized From Fund Raising Commitment
CollaborativeAgreementAmountUtilizedFromFundRaisingCommitment
800000
CY2022Q4 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
0
CY2023Q4 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
0
CY2022Q1 nvct Shares Authorized
SharesAuthorized
65000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023 nvct Common Stock Voting Right
CommonStockVotingRight
1
CY2023 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2023Q2 nvct Percentage Of Shares Outstanding During Period
PercentageOfSharesOutstandingDuringPeriod
0.06
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22260000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19085000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15556655
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12657651
CY2023 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
16691708
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13205888
CY2023 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1135053
CY2022 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
548237
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15556655
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12657651
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.269
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.269
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
35000000.0
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
23000000.0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.05
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.05
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.22
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.22
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9625000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6120000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2236000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
969000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
52000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
52000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2578000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1432000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14491000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8573000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14491000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8573000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8573000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3471000
CY2023 nvct Deferred Tax Asset Valuation Allowance Additions
DeferredTaxAssetValuationAllowanceAdditions
5918000
CY2022 nvct Deferred Tax Asset Valuation Allowance Additions
DeferredTaxAssetValuationAllowanceAdditions
5102000
CY2023 nvct Deferred Tax Asset Valuation Allowance Deductions
DeferredTaxAssetValuationAllowanceDeductions
0
CY2022 nvct Deferred Tax Asset Valuation Allowance Deductions
DeferredTaxAssetValuationAllowanceDeductions
0
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14491000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8573000

Files In Submission

Name View Source Status
0001558370-24-002497-index-headers.html Edgar Link pending
0001558370-24-002497-index.html Edgar Link pending
0001558370-24-002497.txt Edgar Link pending
0001558370-24-002497-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20231231.xsd Edgar Link pending
tmb-20231231x10k.htm Edgar Link pending
tmb-20231231x10k001.jpg Edgar Link pending
tmb-20231231xex19d1.htm Edgar Link pending
tmb-20231231xex21d1.htm Edgar Link pending
tmb-20231231xex23d1.htm Edgar Link pending
tmb-20231231xex23d1003.jpg Edgar Link pending
tmb-20231231xex31d1.htm Edgar Link pending
tmb-20231231xex31d2.htm Edgar Link pending
tmb-20231231xex32d1.htm Edgar Link pending
tmb-20231231xex32d2.htm Edgar Link pending
tmb-20231231xex4d6.htm Edgar Link pending
tmb-20231231xex97d1.htm Edgar Link pending
tmb-20231231_def.xml Edgar Link unprocessable
tmb-20231231_lab.xml Edgar Link unprocessable
tmb-20231231_pre.xml Edgar Link unprocessable
tmb-20231231x10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
tmb-20231231_cal.xml Edgar Link unprocessable